Advertisement
Merck
Subscribe to Merck

The Lead

CHMP Issues Positive Opinion for Merck's Investigational Antibiotic SIVEXTRO®

January 26, 2015 11:00 am | News | Comments

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO® for the treatment of acute bacterial skin and skin structure infections in adults.

Moderna and Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

January 15, 2015 1:32 pm | News | Comments

Moderna Therapeutics has announced a license and collaboration agreement with Merck for the...

Merck Races Bristol-Myers Squibb as it Seeks New OK for Cancer Drug

January 13, 2015 8:22 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Merck is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of...

Lilly, Merck to Collaborate on Immuno-Oncology Combination Regimens in Multiple Types of Cancer

January 13, 2015 8:17 am | News | Comments

Merck and Eli Lilly announced today an oncology clinical trial collaboration to evaluate the...

View Sample

FREE Email Newsletter

Merck Provides Update on Strategic Actions to Transform the Company

January 12, 2015 8:20 am | News | Comments

Merck today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth.

Two Leading Ebola Vaccines Appear Safe, Further Tests Starting

January 9, 2015 8:14 am | by MARIA CHENG, AP Medical Writer | News | Comments

After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines — one made by GlaxoSmithKline and the other licensed by Merck and NewLink — have "an acceptable safety profile."  

EnWave to Build Second Generation Radiant Energy Vacuum Dryer for Merck

December 29, 2014 9:24 am | News | Comments

EnWave Corporation has signed a non-exclusive Research and Development License Agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary to enable testing and advancement of the Company's Radiant Energy Vacuum ("REV™") dehydration technology in the pharmaceutical industry.

Advertisement

NewLink Genetics, Merck Ebola Vaccine Collaboration Supported by $30M Government Award

December 22, 2014 8:52 am | News | Comments

The Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services has awarded NewLink Genetics' subsidiary, BioProtection Systems, as the prime contractor in a $30M contract to support the manufacturing and development activities of its investigational Ebola vaccine candidate.

Merck Acquires OncoEthix for $110M

December 18, 2014 8:05 am | News | Comments

Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.

FDA OKs Gardasil 9 to Prevent Cancers Caused by Five Additional Types of HPV

December 10, 2014 3:27 pm | News | Comments

The FDA has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil, Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.

Merck Advances Breast Cancer Drug

December 10, 2014 1:44 pm | by The Associated Press | News | Comments

Merck will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type of breast cancer.               

Cubist Patent Losses Won't Deter Merck

December 9, 2014 10:03 am | by The Associated Press | News | Comments

Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the company's patents protecting its top-selling antibiotic just hours after the deal was announced this week.  

Advertisement

Sigma-Aldrich Stockholders Approve Acquisition by Merck KGaA

December 8, 2014 8:50 am | News | Comments

Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders.       

Merck Buys Cubist Pharmaceuticals for $8.4B

December 8, 2014 7:53 am | News | Comments

Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.           

Merck and NewLink Genetics to Collaborate on Investigational Ebola Vaccine

November 24, 2014 8:26 am | News | Comments

Merck and NewLink Genetics Corporation have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.       

Study Lifts Cloud Over Heart Drugs Zetia, Vytorin

November 18, 2014 8:31 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.

Merck and Pfizer to Develop Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

November 17, 2014 8:15 am | News | Comments

Merck announced today that it has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

Advertisement

Gene Study Boosts Interest in Heart Drug Zetia

November 12, 2014 5:09 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

Scientists have discovered some rare gene mutations that give people naturally lower cholesterol levels and cut their risk of heart disease in half. The news is of great interest because a drug that mimics these mutations has long been sold without evidence that it cuts the chance of heart disease, even though it lowers cholesterol.

Merck's Third Quarter Net Income Falls But Profits Top Analysts' Estimates

October 27, 2014 8:31 am | News | Comments

Merck's third-quarter net income fell mostly because of large costs tied to acquisitions and divestitures. But the company's adjusted earnings topped Wall Street's view, and it narrowed its full-year adjusted earnings forecast on Monday.  

Merck Ex-Financial Analyst Facing Insider Trading Charge

October 15, 2014 8:14 am | News | Comments

A former senior finance analyst at Merck & Co. is facing an insider trading charge after authorities said Tuesday that he passed secrets to a friend he met at college that earned $722,000 in illegal profits.       

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:15 pm | News | Comments

Merck has completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion.        

Merck KGaA to Buy Sigma Aldrich for $17B

September 22, 2014 7:44 am | by David Mchugh - AP Business Writer - Associated Press | News | Comments

Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.

Merck KGaA Strengthens Executive Board

September 18, 2014 2:20 pm | News | Comments

Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo was appointed to the Executive Board to take over leadership for the Pharma business.

Sun Pharma and Merck Announce $80M Licensing Agreement for Tildrakizumab

September 17, 2014 9:00 am | News | Comments

Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.

Merck KGaA Discontinues Clinical Development Program of Tecemotide for Stage III Non-Small Cell Lung Cancer

September 12, 2014 3:18 pm | News | Comments

Merck KGaA announced that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).

Shortage of Bladder Cancer Drug Could be Tragic for Patients, Doctor Says

September 9, 2014 8:32 am | by Sheryl Ubelacker, The Canadian Press | News | Comments

The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by manufacturing problems at plants operated by two different pharmaceutical companies — Merck and Sanofi Pasteur.        

FDA Approves Keytruda for Advanced Melanoma

September 4, 2014 3:49 pm | News | Comments

The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.       

Pfizer And Merck to Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

August 26, 2014 8:35 am | News | Comments

Pfizer and Merck announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer.

FDA Approves New Sleeping Drug from Merck

August 13, 2014 4:29 pm | by The Associated Press | News | Comments

Merck & Co. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep. The tablet, Belsomra, works by temporarily blocking chemicals known as orexins that control the sleep cycle and can keep people awake at night.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading